Workflow
Cannabix Marijuana Breath Test Featured on the Cover of AlcoPro’s 2026 Product Catalog
Globenewswire· 2026-01-22 13:45
VANCOUVER, British Columbia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) a developer of marijuana and alcohol breath-testing devices, is pleased to announce that its Marijuana Breath Test (“MBT”) will be featured on the cover of the 2026 AlcoPro Inc. product catalogue (see Figure 1). AlcoPro Inc. (“AlcoPro”), based in Knoxville, TN, is a leading U.S. supplier of professional drug and alcohol testing instruments, kits, ...
Leviathan Metals Intersects High-Grade Zinc, Lead and Silver mineralization in trenching at Foča, Bosnia and Herzegovina
Globenewswire· 2026-01-22 13:30
Shallow trenching at the Vrela-Kremin trend returns 14 meters at 7.78% ZnEq within a broader interval of 27 meters at 4.63% ZnEq (T25MAR04), and 12 meters at 8.92% ZnEq within a broader interval 29 meters at 4.67% ZnEq, (T25MAR11).Demonstrates high grade, silver, lead and zinc mineralization over prominent widths, within a broader geochemical and structural corridor striking over 2.6 kilometers. This work sets the stage for drilling at Foča during the 2026 exploration season. VANCOUVER, British Columbia, Ja ...
ASUS Announces Pre-Order Availability in Canada for Zenbook S16 and Zenbook 14
Globenewswire· 2026-01-22 13:30
Core Insights - ASUS has announced the availability of its AI-powered laptops, Zenbook S16 and Zenbook 14, in Canada, featuring advanced AMD Ryzen AI 400 Series processors and designed as Copilot+ PCs [3][18]. Product Overview - The Zenbook S16 (UM5606GA) and Zenbook 14 (UM3406GA) are designed for a wide range of premium mobile users, from creators to professionals and students, emphasizing performance and portability [4]. - Both models are powered by the AMD Ryzen AI 7 445 processor, offering up to 50 TOPS of NPU performance for efficient on-device AI computing [5][12]. Zenbook S16 Features - The Zenbook S16 is ultra-thin at 1.1 cm and weighs 1.5 kg, featuring a 16-inch 3K 120Hz ASUS Lumina OLED display with a peak brightness of up to 1100 nits [5][9]. - It incorporates ASUS' Thincredible thermal architecture, allowing sustained power in a slim design, with a 28W CPU TDP and an 83Wh battery for long productivity hours [7]. - The laptop includes advanced security features such as ASUS Voice Print technology and Windows Hello facial recognition [10]. Zenbook 14 Features - The Zenbook 14 is lightweight at 1.2 kg and 14.9 mm thin, designed for users who prioritize mobility without sacrificing performance [12][13]. - It features a 14-inch ASUS Lumina OLED display with up to 600 nits peak brightness and a 75Wh battery for all-day productivity [15][18]. - The device meets MIL-STD-810H military-grade standards, ensuring durability for daily use [13]. Pricing and Availability - Both laptops are available for pre-order starting January 22, 2026, with shipments expected on February 3, 2026. The Zenbook 14 starts at C$1,599 and the Zenbook S16 at C$2,299 [18].
NetraMark Engages LodeRock Advisors for Strategic Investor Relations and Capital Markets Communications Services
Globenewswire· 2026-01-22 13:30
Core Viewpoint - NetraMark Holdings Inc. has engaged LodeRock Advisors Inc. for strategic investor relations and capital markets communications to enhance its outreach and investor engagement efforts in the pharmaceutical industry [1][2]. Group 1: Investor Relations Strategy - The investor relations program will span 12 months and include a marketing schedule, investor targeting, analysis, outreach, and collaboration with investment dealers for non-deal roadshows [2]. - NetraMark will compensate LodeRock with a monthly fee of CAD $11,000 for these ongoing strategic communication services, starting from January 22, 2026 [3]. Group 2: Company Overview - NetraMark is focused on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions specifically for the pharmaceutical sector, utilizing a unique topology-based algorithm to analyze patient data [6]. - The company's technology allows for the segmentation of diseases and classification of patients based on their sensitivity to drugs and treatment efficacy, enabling the use of smaller datasets for more accurate results [6].
IperionX Receives Prototype Purchase Order for U.S. Army Heavy Ground Combat Systems
Globenewswire· 2026-01-22 13:30
CHARLOTTE, N.C., Jan. 22, 2026 (GLOBE NEWSWIRE) -- IperionX Limited (IperionX) (NASDAQ: IPX, ASX: IPX) has received a US$0.3 million prototype purchase order from American Rheinmetall for the production of 700 lightweight titanium components for U.S. Army heavy ground combat systems. This initial purchase order has the potential to lead to a significantly larger agreement upon successful delivery of this initial scope of work. The components will be manufactured in the United States using 100% recycled tita ...
HomeTrust Bancshares, Inc. Announces Financial Results for the Fourth Quarter of the Year Ended December 31, 2025 and Declaration of a Quarterly Dividend
Globenewswire· 2026-01-22 13:30
Core Insights - HomeTrust Bancshares, Inc. reported a preliminary net income of $16.1 million for Q4 2025, a decrease of 2.2% from Q3 2025, and a net income of $64.4 million for the year 2025, representing a 17.4% increase from 2024 [6][19]. Financial Performance - For Q4 2025, diluted earnings per share (EPS) were $0.93, down from $0.95 in Q3 2025 [9]. - The annualized return on assets (ROA) for Q4 2025 was 1.44%, compared to 1.48% in Q3 2025, while the return on equity (ROE) was 10.63%, down from 11.10% [9]. - The net interest margin decreased to 4.20% in Q4 2025 from 4.31% in Q3 2025 [9]. Dividend Declaration - The Board of Directors declared a quarterly cash dividend of $0.13 per common share, payable on February 26, 2026, to shareholders of record as of February 18, 2026 [2]. Noninterest Income and Expense - Noninterest income for Q4 2025 increased by $645,000, or 7.4%, compared to Q3 2025, totaling $9.396 million [15][17]. - Noninterest expense for Q4 2025 rose by $428,000, or 1.4%, compared to Q3 2025, totaling $31.694 million [18]. Asset Quality - The allowance for credit losses (ACL) on loans was $41.5 million, or 1.16% of total loans, at December 31, 2025, down from $45.3 million, or 1.24%, at December 31, 2024 [36]. - Net loan charge-offs for the year ended December 31, 2025, totaled $9.3 million, compared to $10.8 million for the prior year [37]. Balance Sheet Overview - Total assets decreased by $49.8 million to $4.5 billion, while total liabilities decreased by $98.7 million to $3.9 billion at December 31, 2025 [33]. - Stockholders' equity increased by $48.9 million, or 8.9%, to $600.7 million at December 31, 2025 [34].
GoldHaven Identifies Significant Indium Enrichment with Values up to 334 ppm at Magno
Globenewswire· 2026-01-22 13:30
VANCOUVER, British Columbia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- GoldHaven Resources Corp. ("GoldHaven" or the "Company") (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) is pleased to report further findings from its 2025 surface exploration program highlight indium (In) mineralization at the Magno Property in northwestern British Columbia. The program focused on verifying historical mineral occurrences and significantly expanding the property-wide geochemical dataset employing modern analytical techniques. Highlights: ...
Star Equity Issues Statement on GEE Group’s Lack of Engagement
Globenewswire· 2026-01-22 13:30
Core Viewpoint - Star Equity Holdings, Inc. has proposed a merger with GEE Group, Inc. to enhance shareholder value, but GEE Group has not responded to the proposal despite multiple outreach attempts [1][2][8]. Group 1: Proposal Rationale - GEE Group should consider merging with a larger entity to avoid the pitfalls of remaining a small public company, which incurs high SG&A expenses relative to revenue [2]. - The merger would eliminate duplicative public company costs and create potential cost-saving synergies, enhancing overall performance [2]. - GEE Group's previous acquisitions have underperformed, suggesting that it should focus on being a seller rather than a buyer [2]. Group 2: Financial Performance Concerns - GEE Group's revenue for FY 2025 was $96.5 million, a 41.6% decline from FY 2022 and a 9.8% decline from FY 2024 [3]. - The company reported net losses of $58.8 million over the last two years, including $36.2 million from goodwill impairment, indicating overpayment for past acquisitions [3][4]. - The stock price has declined nearly 92% from five years ago, reflecting market concerns over GEE Group's financial performance and capital allocation [5]. Group 3: Market Sentiment and Management Strategy - GEE Group's stock has traded close to its cash per share since April 2025, signaling a loss of market confidence in its financial and operational strategies [5]. - Despite the stock's decline, GEE Group's management has expressed a preference for acquisitions over share repurchases, which could be detrimental to shareholder value given the high multiples in the staffing industry [6]. - The market sentiment indicates skepticism regarding the board's commitment to enhancing shareholder value through disciplined capital management [6]. Group 4: Benefits of the Proposed Merger - The merger with Star Equity is expected to create significant value for both GEE Group and Star Equity shareholders through operational efficiencies and reduced overhead costs [9][12].
NARMAFOTINIB Large-Scale Manufactre Complete
Globenewswire· 2026-01-22 13:30
Successful completion of the first large-scale manufacture of narmafotinib which produced approx. 13 kg of drug Successful transition of process and production from an R&D facility to a commercial manufacturing environment - a key step in Phase-3 readiness Sufficient drug supply to support Amplia’s pancreatic cancer trials and other planned studies, supporting the Company's clinical development pipeline Melbourne, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF ...
Kearny Financial Corp. Announces Second Quarter Fiscal 2026 Results and Declaration of Cash Dividend
Globenewswire· 2026-01-22 13:30
Core Insights - Kearny Financial Corp. reported a net income of $9.4 million for the quarter ended December 31, 2025, slightly down from $9.5 million in the previous quarter, maintaining a diluted earnings per share of $0.15 [1][24] - The Board of Directors declared a quarterly cash dividend of $0.11 per share, payable on February 18, 2026 [2] - The company experienced a year-over-year expansion in net interest margin by 32 basis points, reaching 2.14%, attributed to strategic balance sheet management and loan portfolio repricing [3][10] Financial Performance - Pre-tax, pre-provision net revenue increased by 3.9% to $12.3 million, indicating strengthening core earnings [6] - Non-performing assets decreased by 20.6% to $51.3 million, representing 0.67% of total assets, reflecting solid credit quality [6][17] - Total deposits rose by $79.7 million, or 1.4%, to $5.71 billion, enhancing funding capacity [6][19] Balance Sheet Highlights - Total assets were reported at $7.62 billion, a decrease of $27.1 million, or 0.4%, from the previous quarter [6][19] - Loans receivable totaled $5.75 billion, down by $14.0 million, or 0.2%, primarily due to reductions in multifamily and residential mortgage loans [6][19] - Borrowings decreased by $111.5 million, or 9.2%, to $1.10 billion, reflecting a reduction in Federal Home Loan Bank advances [6][19] Income Statement Analysis - Net interest income increased by $265,000 to $38.0 million, while total interest income decreased by 2.2% to $80.7 million [10][24] - Non-interest income decreased by $276,000, or 4.7%, to $5.6 million, primarily due to the absence of a non-recurring gain from the previous quarter [10][24] - Non-interest expense decreased by $475,000, or 1.5%, to $31.2 million, driven by declines in salary and benefits and occupancy expenses [10][24] Asset Quality and Capital - The allowance for credit losses was $45.0 million, or 0.78% of total loans, showing a slight decrease from the previous quarter [17] - Book value per share increased by $0.07, or 0.6%, to $11.70, while tangible book value per share rose by $0.07, or 0.7%, to $9.93 [17] - The company's tangible equity to tangible assets ratio was reported at 8.56%, with regulatory capital ratios exceeding all applicable requirements [17][19]